Revenue
$40.1m
+29.1% ↑ vs $31.1m
Full-year Cromwell consolidation and a sharp H2 earnings swing lift reported NPAT while net debt/EBITDAF falls from 11.1x to 5.8x.
Revenue context before the current result.
EBITDAF margin across covered periods.
Operating cash flow across covered periods.
Operating working-capital absorption or release by reporting period.
Key metrics
FY26 vs FY25
Revenue
$40.1m
+29.1% ↑ vs $31.1m
Net profit after tax
$12.9m
+89.7% ↑ vs $6.8m
Net cash inflow from operating activities
$6.4m
+86.9% ↑ vs $3.4m
Full-year dividend per share
0.0c
— vs —
Profit before tax
$13.9m
+107.5% ↑ vs $6.7m
Cash and cash equivalents
$0.11m
-16.7% ↓ vs $0.13m
Total assets
$199.5m
+15.9% ↑ vs $172.1m
What changed
These headline movements are not a like-for-like read: the comparative included a part-period Cromwell contribution and a discontinued Eileen Mary operation, so the year-on-year growth rates carry a basis discontinuity. The cleaner operating anchor is underlying EBITDAF of $6.6m, which the company reconciles to $4.2m in the prior year. Operating cash flow rose to $6.4m from $3.4m, while gross borrowings fell to $38.6m from $46.7m and net debt to EBITDAF moved from 11.1x to 5.8x. A dividend policy was introduced but no FY26 dividend was declared.
What matters
The HY26 release reported H1 NPAT of -$0.0m, so essentially the entire reported full-year NPAT of $12.9m landed in H2 on H2 revenue of around $20.9m. This means investors should treat the PBT and NPAT lines as containing material non-operating items and use EBITDAF as the durable earnings reference.
Net debt fell by roughly $8m and net debt/EBITDAF improved from 11.1x to 5.8x. Leverage remains elevated for an aged-care operator, but the trajectory expands capacity for the acquisition activity flagged in the HY26 release.
Management set a dividend policy but declared no FY26 distribution. Operating free cash flow remained slightly negative at -$0.2m (per the company's OFCF reconciliation), and cash on balance sheet is $0.1m, so near-term distributable capacity is constrained even as the policy signals capital-return intent.
Expectations
The release describes Cromwell as now embedded and Nelson Street as effectively full, and the HY26 release referenced early-stage acquisition negotiations. The result supports the operational repositioning narrative at the EBITDAF level, but with H2 carrying virtually all reported earnings and a basis change from the acquisition and disposal, the forward run-rate cannot be cleanly inferred from the headline. Investors should weight EBITDAF rather than NPAT when projecting forward, and watch HY27 for confirmation that the H2 EBITDAF pace (roughly $4.1m on the implied split) reflects an underlying base rather than seasonal occupancy strength.
Quality of result
Net cash from operations of $6.4m sits close to this number, so cash conversion at the EBITDAF level looks reasonable. Operating free cash flow improved to -$0.2m from -$1.3m, indicating that after capex of $0.5m, interest, and lease costs the business is roughly at cash breakeven - an improvement, but not yet a source of distributable surplus.
The less durable component is the gap between EBITDAF and reported PBT/NPAT. The H2 swing from a near-breakeven H1 to roughly $13.0m of H2 NPAT cannot be reconciled to EBITDAF and is consistent with property revaluation or other below-the-line gains typical for aged-care operators, though the source material provided does not separately disclose the driver. The effective tax rate of 7.3% (prior: 1.6%) is consistent with non-taxable or low-tax gains in that line, which reinforces the view that the NPAT growth is not a clean operating signal. The basis discontinuity from a full-year Cromwell consolidation against a part-period prior also affects revenue and earnings growth comparability.
Unresolved
This briefing cannot assess the specific composition of the $7.3m gap between EBITDAF and PBT because the source material does not separately disclose revaluation, fair-value, or other non-operating items.
Chat
Ask follow-up questions about Promisia Healthcare's FY26 result.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Open to load analytical metrics.
Open to load key metrics.
PHL FY26 NZX Results Announcement
FY26 / results announcementPHL FY26 Preliminary Financial Statements
FY26 / financial reportPHL FY26 Results Announcement
FY26 / results releasePHL FY26 Results Presentation
FY26 / results presentationPHL 2025 Annual Report
FY25 / financial reportPHL HY26 Preliminary Financial Statements
HY26 / financial reportPHL HY26 Results Announcement
HY26 / results releasePHL HY26 NZX Results Announcement
HY26 / results announcementFY26 Earnings Guidance Upgrade
FY26 / commentaryPresentation - ASM 2025
HY26 / commentaryRelated insights
Cross-company views selected from the metrics in this briefing.
Earnings quality and statutory distortions
PBT and NPAT growth diverged by 17.8pp, with a distortion flag in the result.
Leverage and balance-sheet risk
Net debt / EBITDA is 5.82x, -5.28x versus the prior comparable period.
Revenue growth context
Revenue growth was 29.1% for this reporting period.
Cash conversion quality
This result converted 96.2% of EBITDA to operating cash flow, +15.0pp versus the prior comparable period.
Get the next Promisia Healthcare briefing and related NZX reporting-season updates by email.